Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-TATE in Advanced Metastatic NETs
NCT03478358Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of EBTATE in neuroendocrine tumors (NETs) (6 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change of standardized uptake value of 68Ga-DOTA-TATE at 1 year and Safety of 177Lu-DOTA-EB-TATE at 1 year. Status: unknown.
02
Drugs
EBTATE
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03478358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478358.